GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Short Interest

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Freeline Therapeutics Holdings's Short Interest

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Short Interest falls into.



Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.